Biotech course for industry pros by Biocom and National University

We’re thrilled to announce a new milestone for Single Cell Discoveries! We are now the first European company to join the Parse Biosciences Certified Service Provider (CSP) Program. Through this partnership, we’re combining our deep expertise in single-cell science with Parse’s scalable, fixation-friendly technology. This allows us to continue empowering researchers across Europe and beyond with high-quality, accessible single-cell sequencing services. From focused pilot studies to atlas-scale projects, this collaboration expands what’s possible in single-cell research, while ensuring the rigor, scalability, and speed modern science demands. Read the full press release here: https://lnkd.in/efEA9vHX

SCD becomes Europe’s first Parse Certified Service Provider! As one of our founding principles, we have always been technology-agnostic — because no single method can answer every biological question. Our mission is to evaluate, adopt, and scale the best technologies so our clients can push their science forward. With that in mind, I’m excited to announce that Single Cell Discoveries is now the first Certified Service Provider in Europe for Parse Biosciences. Parse has developed a powerful platform and their team has greatly expanded what’s possible in single-cell sequencing. This milestone reflects our broader commitment: working across the leading single-cell, bulk, and spatial technologies to deliver the right solution for each project. With this new partnership, we’re looking forward to scaling projects together — and continuing to give researchers the right method for the right question!

CN Bio launches all-in-one Organ-on-a-chip system, PhysioMimix® Core. The system combines the capabilities of the Company’s existing suite of instruments to deliver single-organ, multi-organ and higher-throughput configurations within one scalable platform. Building on the history and success of the PhysioMimix brand, the System is adaptable across the entire drug discovery and development pipeline and is designed to unlock even deeper insights into human biology. Read the full press release here: https://bit.ly/3W6HxEv

At #EMBC2025, Dame Molly Stevens shared how bioengineered materials are transforming healthcare - from affordable diagnostics to advanced therapeutics and regenerative medicine. Hear how her interdisciplinary team is designing cutting-edge solutions that bring science out of the lab and into society. Watch the full interview now on the IEEE EMBS YouTube channel: https://lnkd.in/ghfJpqfn #Bioengineering #Biomaterials #Diagnostics #RegenerativeMedicine #EMBSTV

𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐟𝐫𝐨𝐦 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐨𝐧 𝐓𝐚𝐫𝐠𝐞𝐭 𝟐𝟎𝟐𝟓 - 𝐊𝐞𝐲 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐁𝐨𝐬𝐭𝐨𝐧 Lately, our CEO, 𝐃𝐫. Jacek Olczak, attended 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐨𝐧 𝐓𝐚𝐫𝐠𝐞𝐭 𝟐𝟎𝟐𝟓, one of the world’s leading meetings dedicated to emerging drug targets and drug discovery technologies. The event brought together over a thousand researchers to discuss the latest progress across target discovery, molecular design, and next-generation therapeutic modalities. Here are three insights that particularly resonated within our scientific team at Ascentia: 1️⃣ 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐠𝐥𝐮𝐞𝐬, 𝐏𝐑𝐎𝐓𝐀𝐂𝐒 𝐚𝐧𝐝 𝐦𝐮𝐥𝐭𝐢 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐬 𝐚𝐫𝐞 𝐬𝐭𝐢𝐥𝐥 𝐢𝐧 𝐟𝐚𝐬𝐡𝐢𝐨𝐧 2️⃣ 𝐆𝐏𝐂𝐑𝐬 𝐚𝐫𝐞 𝐬𝐭𝐢𝐥𝐥 𝐢𝐧 𝐟𝐨𝐜𝐮𝐬 𝐚𝐬 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐭𝐚𝐫𝐠𝐞𝐭𝐬 3️⃣ 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐜𝐫𝐨𝐬𝐬 𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐞𝐬 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐬 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧 The scientific dialogue at #DOT2025 reaffirmed what drives us: bridging fundamental insights with translational outcomes through rigorous, collaborative research. #DrugDiscovery #CRO #BostonDOT #MedicinalChemistry #TranslationalResearch

Excited to share just some of the data from our lead first-in-class (FIC) oncology programme, which indirectly targets the “undruggable” Myc — one of the holy grails of cancer biology. - Orally bioavailable small molecule(s) ✔️ - Extremely selective ✔️ - Myc downregulation ✔️ - Tumour regression ✔️ - Multiple liquid and solid tumours ✔️ - Well tolerated ✔️

🚀 When drug discovery goes turbo: In our latest preprint, we turned catalog browsing into fast-track innovation. Check it out 👇 Using a SAR-by-Catalog workflow supported by computational modeling💻, we rapidly optimized our best-in-class CD28 inhibitor, mapping structural analogs straight from commercial catalogs 🛒to discover BPU11, a next-generation small molecule CD28 inhibitor with enhanced potency, stability, and immune activity in ex vivo models🧫. 💡This is what modern drug discovery looks like: fast, data-driven, and translational. 📖Read the full paper →https://lnkd.in/gnYafHKV 🙌Grateful to the talented Gabr Lab team behind this discovery: Saurabh Upadhyay, PhD., Hossam Nada, and Sungwoo Cho #SARbyCatalog #MedicinalChemistry #DrugDiscovery #Immunotherapy #CD28 #Innovation #SmallMolecules

Published this week in Blood by colleagues (Etra A, Ferrara JLM, Levine JE, 2025), this marks a turning point for the entire cellular therapy landscape. For those of us working to translate MSC science into regulatory-approved products, this milestone validates two decades of research, persistence, and manufacturing optimization. The path forward is clearer than ever — refining potency assays, ensuring reproducibility, and expanding clinical evidence toward broader approvals and new indications. Proud to be part of this ongoing journey driving MSCs from the lab to real-world clinical impact.@mesenchymalstemcells

Free Webinar – Wednesday, 15 October 2025 - 2.00 p.m. BST Ask the Experts: Extracellular Vesicle Purification and EXO-NET Workflow Extracellular vesicles (EVs) are a fast-moving area of biomarker discovery, but progress can be slowed by labour-intensive workflows and inconsistent recovery. In this live Q&A session, experts from INOVIQ Ltd (ASX:IIQ), The University of Queensland, and Promega will discuss: • How EXO-NET® Pan Exosome Capture reagents enable EV isolation with reduced background • How automated workflows on the Maxwell® RSC, KingFisher® Apex, and other platforms streamline EV enrichment and miRNA extraction • Practical insights to help accelerate EV-based research Register at: https://bit.ly/3KHZ8QA #ExtracellularVesicles #CellTherapy #MolecularBiology

🧬 Leverage the MULTISCREEN™ Ortholog GPCR Panel to uncover species-specific differences early and avoid translational setbacks. Integrating ortholog screening strengthens hit-to-lead success by guiding SAR, prioritizing robust compounds, and improving confidence in translational outcomes. 👉 Learn more: https://hubs.la/Q03LzB220 #GPCR #DrugDiscovery #Biotech #Research #Multispan